These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10472209)

  • 1. Rapacuronium (Org 9487): do we have a replacement for succinylcholine?
    Goulden MR; Hunter JM
    Br J Anaesth; 1999 Apr; 82(4):489-92. PubMed ID: 10472209
    [No Abstract]   [Full Text] [Related]  

  • 2. The hemodynamic effects of rapacuronium in patients with coronary artery disease: succinylcholine and vecuronium compared.
    Delboy NJ; Tomichek RC; Shields JA
    Anesth Analg; 2002 May; 94(5):1100-6, table of contents. PubMed ID: 11973169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of rapacuronium bromide, a new short-acting neuromuscular blocking agent.
    Larijani GE; Zafeiridis A; Goldberg ME
    Pharmacotherapy; 1999 Oct; 19(10):1118-22. PubMed ID: 10512060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of recovery following rapacuronium, with and without neostigmine, and succinylcholine.
    Hayes A; Breslin D; Reid J; Mirakhur RK
    Anaesthesia; 2000 Sep; 55(9):859-63. PubMed ID: 10947748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intubating conditions after rapacuronium (Org 9487) and succinylcholine following rapid sequence induction in adult patients.
    Sparr HJ; Mellinghoff H; Blobner M; Nöldge-Schomburg G
    Br J Anaesth; 1999 Apr; 82(4):537-41. PubMed ID: 10472218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapacuronium: why did it fail as a replacement for succinylcholine?
    White PF
    Br J Anaesth; 2002 Feb; 88(2):163-5. PubMed ID: 11878650
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapacuronium: clinical pharmacology.
    Mirakhur RK; McCourt KC
    Eur J Anaesthesiol Suppl; 2001; 23():77-82. PubMed ID: 11766252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer neuromuscular blocking agents: how do they compare with established agents?
    Sparr HJ; Beaufort TM; Fuchs-Buder T
    Drugs; 2001; 61(7):919-42. PubMed ID: 11434449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of neuromuscular and cardiovascular effects of two doses of rapacuronium (ORG 9487) versus mivacurium and succinylcholine.
    Miguel R; Witkowski T; Nagashima H; Fragen R; Bartkowski R; Foldes FF; Shanks C
    Anesthesiology; 1999 Dec; 91(6):1648-54. PubMed ID: 10598606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromuscular blocking and cardiovascular effects of Org 9487, a new short-acting aminosteroidal blocking agent, in anaesthetized animals and in isolated muscle preparations.
    Muir AW; Sleigh T; Marshall RJ; Pow E; Anderson KA; Booij LH; Hill DR
    Eur J Anaesthesiol; 1998 Jul; 15(4):467-79. PubMed ID: 9699106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromuscular monitoring: does it make a difference?
    Martin R; Bourdua I; Thériault S; Tétrault JP; Pilote M
    Can J Anaesth; 1996 Jun; 43(6):585-8. PubMed ID: 8773865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapacuronium: an alternative to succinylcholine for electroconvulsive therapy.
    Kadar AG; Kramer BA; Barth MC; White PF
    Anesth Analg; 2001 May; 92(5):1171-2. PubMed ID: 11323342
    [No Abstract]   [Full Text] [Related]  

  • 13. Determining the potency of neuromuscular blockers: are traditional methods flawed?
    Kopman AF; Lien CA; Naguib M
    Br J Anaesth; 2010 Jun; 104(6):705-10. PubMed ID: 20430764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of rapacuronium bromide.
    Wight WJ; Wright PM
    Clin Pharmacokinet; 2002; 41(13):1059-76. PubMed ID: 12403643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of the neuromuscular blocking agents.
    Larijani GE; Gratz I; Silverberg M; Jacobi AG
    DICP; 1991 Jan; 25(1):54-64. PubMed ID: 1672571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged duration of neuromuscular block with rapacuronium in the presence of sevoflurane.
    Cara DM; Armory P; Mahajan RP
    Anesth Analg; 2000 Dec; 91(6):1392-3, TOC. PubMed ID: 11093986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early reversal of rapacuronium with neostigmine.
    Purdy R; Bevan DR; Donati F; Lichtor JL
    Anesthesiology; 1999 Jul; 91(1):51-7. PubMed ID: 10422928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapacuronium and bronchospasm.
    Goudsouzian NG
    Anesthesiology; 2001 May; 94(5):727-8. PubMed ID: 11388519
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapacuronium: first experience in clinical practice.
    Bartkowski RR; Witkowski TA
    Eur J Anaesthesiol Suppl; 2001; 23():90-3. PubMed ID: 11766254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of the association of depolarizing and non-depolarizing muscle relaxants].
    Foldes FF
    Anesth Analg (Paris); 1971; 28(5):859-69. PubMed ID: 4258297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.